RJA
TVTX icon

Raymond James & Associates’s Travere Therapeutics TVTX Stock Holding History

Raymond James & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$154K Buy
+11,043
New +$115K ﹤0.01% 3703

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Raymond James & Associates's TVTX Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Travere Therapeutics (TVTX) in Q3 2024: 11,043 shares worth $154K. The stake represents ﹤0.01% of the portfolio and ranks #3703 among its holdings.

178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

  • Raymond James & Associates held 11,043 shares of Travere Therapeutics worth $154K as of Q3 2024.
  • Travere Therapeutics was a new Raymond James & Associates position in Q3 2024.
  • Travere Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3703 holding.
  • 178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.